SNY Sanofi

48.73
-0.87  -2%
Previous Close 49.6
Open 49.54
Price To Book 1.96
Market Cap 122,061,253,858
Shares 2,504,848,222
Volume 2,324,079
Short Ratio
Av. Daily Volume 1,967,762
Stock charts supplied by TradingView

NewsSee all news

  1. Sanofi Completes Acquisition of Synthorx, Inc.

    PARIS, Jan. 23, 2020 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN)) announced today the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The

  2. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  3. Sanofi awarded $226 million by US government to expand pandemic influenza preparedness

    SWIFTWATER, Pa., Dec. 9, 2019 /PRNewswire/ -- Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services (HHS) to increase the

  4. Pivotal data from Phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session

    CAMBRIDGE, Mass., Nov. 21, 2019 /PRNewswire/ -- Full data from the pivotal Phase 3 CARDINAL trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) with a history of

  5. New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- New clinical data from Sanofi's oncology and rare blood disorders portfolios and pipelines will be featured, including four oral presentations and 18 posters, at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data presented at ASH December 10, 2019. Primary and secondary endpoints met.
Sutimlimab (BIVV009) - Cardinal
Cold agglutinin disease
FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
Approval announced December 11, 2017.
Admelog (insulin lispro injection)
Diabetes
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial commenced 4Q 2017. Data due 2020.
Efpeglenatide
Type 2 diabetes
sBLA filing due 4Q 2019. Moved to 1Q 2020 due to no update.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
PDUFA date April 30, 2020.
Isatuximab
Refractory Multiple Myeloma
Phase 3 data due 2Q 2020.
Avalglucosidase alfa (NeoGAA) - COMET
Pompe disease
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 interim analysis November 5, 2019 noted trial to continue as planned. Next interim look due 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 data due 1Q 2020.
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 3 data due 2020.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2 data due 2020.
Dupixent (dupilumab)
Peanut Allergy
Phase 2 portion of Phase 2/3 trial due 2020.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 ongoing.
Fitusiran (ATLAS)
Hemophilia
Approved January 23, 2019.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 2 data due 1Q 2020.
SAR442168 (PRN2246)
Multiple sclerosis
FDA approval announced May 1, 2019.
Dengvaxia
Dengue
FDA Approval announced February 6, 2019.
Caplacizumab
Acquired thrombotic thrombocytopenic purpura (aTTP)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)
Asthma
Phase 3 data due 1Q 2020.
Isatuximab - IKEMA
Refractory Multiple Myeloma
PDUFA date April 25, 2020.
MenQuadfi
Meningococcal meningitis
Phase 2 data due 3Q 2020.
SAR440340 / REGN3500
Atopic dermatitis
Phase 2 pivotal data due 2H 2020.
Cemiplimab
Basal cell carcinoma
Phase 1 biomarker data from first cohort to be presented 1H 2020.
THOR-707
Soild tumors
Phase 3 enrolment to be completed 2H 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)

Latest News

  1. Sanofi Completes Acquisition of Synthorx, Inc.

    PARIS, Jan. 23, 2020 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN)) announced today the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The

  2. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  3. Sanofi awarded $226 million by US government to expand pandemic influenza preparedness

    SWIFTWATER, Pa., Dec. 9, 2019 /PRNewswire/ -- Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services (HHS) to increase the

  4. Pivotal data from Phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session

    CAMBRIDGE, Mass., Nov. 21, 2019 /PRNewswire/ -- Full data from the pivotal Phase 3 CARDINAL trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) with a history of

  5. New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- New clinical data from Sanofi's oncology and rare blood disorders portfolios and pipelines will be featured, including four oral presentations and 18 posters, at the

  6. FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

    PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years

  7. Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

    BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar

  8. Sanofi Q3 well on track

    PARIS, Oct. 31, 2019 /PRNewswire/ -- Sanofi (NASDAQ:SNY, EURONEXT: SAN))  Q3 2019 Change Changeat CER 9M 2019 Change Changeat CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS net income

  9. Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

    PARIS, Oct. 15, 2019 /PRNewswire/ -- Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using

  10. New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

    PARIS, Sept. 30, 2019 /PRNewswire/ -- Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and

  11. Sanofi Canada receives Gold-Level Parity Certification

    Source: Sanofi (EURONEXT: SAN) (NASDAQ:SNY) First global biopharmaceutical company with a presence in Canada to be certified by Women in Governance LAVAL, QC, Sept. 26, 2019 /CNW Telbec/ - Sanofi Canada is pleased to

  12. Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (NASDAQ:SNY) to advance the

  13. Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

    Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally